Somatic Solid Tumour Liquid Panel

​20 ml of blood collected in K₂EDTA blood collection tubes.

​

This assay can be used to determine the presence of genomic alterations in circulating tumour nucleic acids in patients' peripheral blood that would predict response of a cancer to targeted therapy (predictive testing). Only SNVs and short delins are validated for this assay.

Click here to view more details on SSTP Liquid assay including the full list of gene coverage.

Click here to view CPOE ordering instructions for SSTP Liquid (for relevant SingHealth institutions.

​Specimens should be sent to 20 College Road, Academia building, Diagnostic Tower, Level 8, Client and Specimen Management (CSM).

Specimens should reach CSM within 2 hours from the time of blood draw, after which the specimen may be rejected. 

Specimens are received only on Monday – Friday; 8.45am – 4pm (excluding public holidays).

​Amplicon-based next generation sequencing (NGS) assay incorporated with molecular tagging allowing sensitive detection of circulating cell-free tumour nucleic acids in the peripheral blood (liquid biopsy). 

​Gene variants (SNVs and short insertions/deletions) are detected by this assay. Gene amplifications and fusions are also tested and reported but the sensitivity and specificity of the assay for gene amplification and fusion have not been validated.

​10 working days from day of test set up.

​Wednesday (Thursday if Wednesday falls on a public holiday)